文献速递肝病消化道出血

阿伐曲泊帕在操作前给药可减少慢性肝病合并血小板减少患者对血小板输注的需求

Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
PubMed 文献 · Gastroenterology · 2018-05-17

两项随机、安慰剂对照的3期试验(ADAPT-1和ADAPT-2)评估了阿伐曲泊帕在慢性肝病合并血小板减少患者接受计划性操作前升高血小板的安全性和有效性。结果显示,阿伐曲泊帕组达到主要终点(操作后7天内无需血小板输注或出血抢救性操作)的患者比例显著高于安慰剂组,且不良事件发生率与严重程度与安慰剂组相似。

要点

  • 阿伐曲泊帕在ADAPT-1和ADAPT-2中均显著提高操作后7天内无需血小板输注或出血抢救性操作的患者比例。
  • 阿伐曲泊帕组血小板计数升高,且操作日达到目标血小板计数≥50×10^9/L的患者比例高于安慰剂组。
  • 阿伐曲泊帕组与安慰剂组的不良事件发生率和严重程度相似。

主要发现

  • ADAPT-1中,接受60 mg阿伐曲泊帕的患者65.6%达到主要终点,接受40 mg阿伐曲泊帕的患者88.1%达到主要终点,安慰剂组分别为22.9%和38.2%(P均<.0001)。
  • ADAPT-2中,接受60 mg阿伐曲泊帕的患者68.6%达到主要终点,接受40 mg阿伐曲泊帕的患者87.9%达到主要终点,安慰剂组分别为34.9%和33.3%(P均<.001)。
  • 阿伐曲泊帕导致血小板计数测量值升高,并使操作日达到目标血小板计数≥50×10^9/L的患者比例高于安慰剂组。
  • 阿伐曲泊帕组与安慰剂组的不良事件发生率和严重程度相似,且与慢性肝病人群预期的不良事件一致。

关键数值与推荐

  • 主要终点为计划性操作后7天内无需血小板输注或出血抢救性操作的患者比例。
  • 基线血小板计数低于40×10^9/L的患者接受阿伐曲泊帕60 mg每日一次,共5天;基线血小板计数40至低于50×10^9/L的患者接受阿伐曲泊帕40 mg每日一次,共5天。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients with thrombocytopenia and chronic liver disease (CLD) may require platelet transfusions before scheduled procedures to decrease risk of bleeding. We performed 2 randomized, placebo-controlled, phase 3 trials in patients with thrombocytopenia and CLD undergoing scheduled procedures to evaluate the safety and efficacy of avatrombopag in increasing platelet counts in this patient population. METHODS: In the ADAPT-1 and ADAPT-2 studies, adults with thrombocytopenia and CLD (n = 231 and n = 204, respectively) were in 1 of 2 cohorts according to their baseline platelet count (below 40 × 109/L or 40 to below 50 × 109/L) and within each cohort were randomized (2:1) to receive 5 daily doses of avatrombopag (60 mg if baseline platelet count below 40 × 109/L or 40 mg if 40 to below 50 × 109/L) or placebo. ADAPT-1 was conducted at 75 study sites in 20 countries, from February 2014 through January 2017, and ADAPT-2 was conducted at 74 sites in 16 countries, from December 2013 through January 2017. The primary endpoint was the proportion of patients not requiring platelet transfusions or rescue procedures for bleeding up to 7 days after a scheduled procedure. RESULTS: In the ADAPT-1 study, 65.6% of patients who received 60 mg avatrombopag and 88.1% of patients who received 40 mg avatrombopag met the primary endpoint compared with 22.9% and 38.2% of patients receiving placebo, respectively (P < .0001 for both). In the ADAPT-2 study, 68.6% of patients who received 60 mg avatrombopag and 87.9% of patients who received 40 mg avatrombopag met the primary endpoint compared with 34.9% and 33.3% of patients who received placebo, respectively (P < .001 for both). Avatrombopag led to a measured increase in platelet counts and increased the proportion of patients who achieved the target platelet count ≥ 50 × 109/L on procedure day vs placebo. The incidence and severity of adverse events were similar for the avatrombopag and placebo groups and were consistent with those expected in the CLD population. CONCLUSIONS: In 2 phase 3 randomized trials, avatrombopag was superior to placebo in reducing the need for platelet transfusions or rescue procedures for bleeding in patients with thrombocytopenia and CLD undergoing a scheduled procedure. ClinicalTrials.gov nos.: NCT01972529 and NCT01976104.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Terrault N, Chen YC, Izumi N, et al. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia. Gastroenterology. 2018. PMID: 29778606. doi:10.1053/j.gastro.2018.05.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。